Trial · NCT04762277
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Total Abscess and Inflammatory Nodule Count at Week 12 | Placebo | -34.7 | Standard Error 11.1 | percent change | |
| Percent Change From Baseline in Total Abscess and Inflammatory Nodule Count at Week 12 | Spesolimab | -38.8 | Standard Error 7.5 | percent change | |
| Percent Change From Baseline in Draining Fistula Count at Week 12 | Placebo | 56.6 | Standard Deviation 23.0 | percent change | |
| Percent Change From Baseline in Draining Fistula Count at Week 12 | Spesolimab | -40.1 | Standard Deviation 16.8 | percent change | |
| Achievement of Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | Placebo | 0.176 | proportion of patients | ||
| Achievement of Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | Spesolimab | 0.314 | proportion of patients | ||
| Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 12 | Placebo | 4.9 | Standard Error 4.7 | units on a scale | |
| Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 12 | Spesolimab | -9.0 | Standard Error 3.2 | units on a scale | |
| Absolute Change From Baseline in Hidradenitis Suppurativa Area and Severity Index (HASI) Score at Week 12 | Placebo | -3.8 | Standard Error 6.9 | units on a scale | |
| Absolute Change From Baseline in Hidradenitis Suppurativa Area and Severity Index (HASI) Score at Week 12 | Spesolimab | -23.6 | Standard Error 4.7 | units on a scale | |
| Achievement of Hidradenitis Suppurativa Physician Global Assessment (HS-PGA) Score of 0 or 1 at Week 12 | Placebo | 0.000 | proportion of patients | ||
| Achievement of Hidradenitis Suppurativa Physician Global Assessment (HS-PGA) Score of 0 or 1 at Week 12 | Spesolimab | 0.057 | proportion of patients | ||
| Achievement of at Least 30% Reduction From Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of HS Pain at Week 12 | Placebo | 0.059 | proportion of patients | ||
| Achievement of at Least 30% Reduction From Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of HS Pain at Week 12 | Spesolimab | 0.229 | proportion of patients | ||
| Occurrence of Complete Elimination of Draining Fistulas at Week 12 | Placebo | 0.067 | proportion of patients | ||
| Occurrence of Complete Elimination of Draining Fistulas at Week 12 | Spesolimab | 0.250 | proportion of patients | ||
| Occurrence of at Least One Flare at Week 12 | Placebo | 0.176 | proportion of patients | ||
| Occurrence of at Least One Flare at Week 12 | Spesolimab | 0.086 | proportion of patients | ||
| Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 12 | Placebo | -2.8 | Standard Error 1.8 | units on a scale | |
| Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 12 | Spesolimab | -2.8 | Standard Error 1.2 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04762277/results